Program for all days

• High level summary of the two previous webinars High Level Summary of the Two Previous Webinars
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada
• Designing Trials for Inclusivity and Generalizability
  Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland
• Trials Without Borders
  RathikaKrishnasamy Speaker Rathika.Krishnasamy@health.qld.gov.auAustralia
• Use of Novel Tools
  Pedro HenriqueFranca Gois Speaker pedro.francagois@health.nsw.gov.auAustralia
• Q&A Session

• Japanese Perspective
  MegumiOshima Speaker mgm_oshima@yahoo.co.jpJapan
• African Perspective
  RobertKalyesubula Speaker rkalyesubula@gmail.comUganda
• Insights on Consent Challenges in Low and Middle-income Countries
  ShuchiAnand Speaker sanand2@stanford.eduUnited States
• Closing the Loop: Returning Results to Participants: Why and How
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada

  BillWang Speaker billwang1968@yahoo.comHong Kong, China
• Q&A Session

• Practical Aspects of Implementation Science; Hands-on Studies
  Tae WonYi Speaker taewon.yi@gmail.comCanada
• Value of Implementation Science
  RukshanaShroff Speaker Rukshana.Shroff@gosh.nhs.ukUnited Kingdom
• Implementation Science in Digital Health: Clinical Trials Using Mobile Applications for Patient Interventions
  YusukeSakaguchi Speaker sakaguchi@kid.med.osaka-u.ac.jpJapan
• Take Home Messages
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia

• Remodel Overview - Framework And Key Outcomes
  PetterBjornstad Speaker petter.m.bjornstad@cuanschutz.eduUnited States
• Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial
  DavidCherney Speaker david.cherney@uhn.on.caCanada
• ACHIEVE
  MichaelWalsh Speaker lastwalsh1975@gmail.comCanada
• B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil
  JulienHogan Speaker julien.hogan2@aphp.frFrance
• Q&A Session

• ASPIRE (Aspirin in Dialysis PTS/ China): Large Pragmatic Trial
  XueqingYu Speaker yuxueqing@gdph.org.cnChina
• RESOLVE (NA CONCENTRTION IN DIALYSIS POPULATIONS: GLOBAL): CLUSTER RANDOMIZED TRIAL
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia
• VOICE
  ShuchiAnand Speaker sanand2@stanford.eduUnited States
• TEST PD
  JosephineChow Speaker Josephine.Chow@health.nsw.gov.auAustralia
• Renal Life Cycle
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far
  Selvin Sundar RajMani Speaker selvinsr@gmail.comIndia
• Q&A

• Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
  XiaobingYang Speaker yxb7829@163.comChina
• Evaluating the Effect of Sparsentan vs Irbesartan on Urine Inflammatory and Profibrotic Biomarkers in the Phase 3 Protect Trial of Patients With Immunoglobulin a Nephropathy
• Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III Applause-IgAN Study
  VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
• Q&A

• Advancing the Next Wave of Therapies in Chronic Kidney Disease
• Effects of Finerenone on Biomarkers: Mechanistic Insights From Proteomic Analyses in Clinical Trials
  MarioBerger Speaker mario.berger@bayer.comGermany
• Future Directions in CRM Care: Advancing Research and Therapeutic Innovation
  AntonioGarreta Rufas Speaker antonio.garreta_rufas@boehringer-ingelheim.comGermany
• Innovative Strategies for Clinical Trial Design in IgAN
• Improving Outcomes in Complement-mediated Kidney Diseases
  Marianne Silkjær Nielsen Speaker Msn@compcure.orgSwitzerland
• Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial
  ManuelMayrdorfer Speaker mumf@novonordisk.comDenmark
• Why? When? How? How to Maximize Patient Outcomes From the Start of Dialysis
  PeterRutherford Speaker peter.rutherford@vantive.comSwitzerland

• Kidney International in Focus: Annual Highlights
  PierreRonco Speaker pierreronco@yahoo.frFrance
• ISN-KI Fellows: Showcasing Excellence Part 1: Pediatrics
  GabrielCara-Fuentes Speaker Gabriel.CaraFuentes@NationwideChildrens.orgUnited States
• ISN-KI Fellows: Showcasing Excellence Part 2: Clinical Nephrology
  SaharKoubar Speaker skoubar@umn.eduUnited States
• ISN-KI Fellows: Showcasing Excellence Part 3: Epidemiology & Clinical Trials
  DavidTunnicliffe Speaker david.tunnicliffe@sydney.edu.auAustralia
• ISN-KI Fellows: Showcasing Excellence Part 4: Basic & Translational Science
  NahidTabibzadeh Speaker nahid.tabibzadeh@inserm.frFrance
• Kidney International Reports in Focus: Annual Highlights
  JaiRadhakrishnan Speaker jr55@cumc.columbia.eduUnited States
• Kidney International Reports in Focus: Annual Highlights
  SumitMohan Speaker mohan.sumit@gmail.comUnited States
• Kidney International Reports in Focus: Annual Highlights
  SumitMohan Speaker mohan.sumit@gmail.comUnited States
• Celebrating Excellence: Best Reviewer Awards Presentation
  BradRovin Speaker rovin.1@osu.eduUnited States
• Presentation of Basic Science Awards (Early Career Researcher Awards)
  BERNHARDDUMOULIN Speaker bernhard.dumoulin@gmail.comUnited States
• Presentation of Clinical Science Awards (Early Career Researcher Awards)
  Joint Presentations
  Louis-CharlesDesbiens Speaker louis-charles.desbiens@umontreal.caCanada
• ISN-KI fellows: What Have They Become?
  GermaineWong Speaker germaine.wong@health.nsw.gov.auAustralia

• Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial (Tickers_hd)
  ClaraBohm Speaker cbohm@sogh.mb.caCanada
• Effect of Finerenone on Circulating Biomarkers: A Confidence Analysis
  MarioBerger Speaker mario.berger@bayer.comGermany
• Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the Confidence Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
  RajivAgarwal Speaker ragarwal@iu.eduUnited States
• Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
  Naya Huang Speaker huangnaya@163.comChina

• Advancing Clinical Trials: Empowering the Kidney Community Through Clinical Trial Awareness
  Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland
• The ISN TrialWatch: Bringing the Latest Evidence to the Kidney Community
  MeganBorkum Speaker mborkum@gmail.comCanada
• The ISN Guide for Everyone: Making Clinical Research Accessible and Meaningful
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada